Jayvant Heera Selected Research

Maraviroc

1/2019	No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.
1/2017	Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
11/2015	Corrigendum. Hepatic Safety in Subjects With HIV-1 and Hepatitis C and/or B Virus: A Randomised, Double-Blind Study of Maraviroc vs Placebo in Combination With Antiretroviral Agents.
6/2015	Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay.
3/2015	Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.
3/2014	Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
5/2013	Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
3/2012	Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.
12/2010	Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
11/2010	Hepatic safety and tolerability in the maraviroc clinical development program.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jayvant Heera Research Topics

Disease

6	Infections 01/2019 - 03/2010
4	Hepatitis C 01/2017 - 04/2014
2	HIV Infections (HIV Infection) 06/2015 - 01/2015
2	Hyperbilirubinemia 02/2013 - 11/2010
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2017
1	Fibrosis (Cirrhosis) 01/2017
1	Chronic Kidney Failure (Chronic Renal Failure) 05/2013
1	Hepatitis B 03/2012
1	Inflammation (Inflammations) 10/2010
1	Neoplasms (Cancer) 05/2010

Drug/Important Bio-Agent (IBA)

13	Maraviroc FDA Link 01/2019 - 03/2010
3	efavirenz (Sustiva)FDA Link 03/2014 - 03/2010
2	Anti-Retroviral Agents (Antiretroviral Agents)IBA 11/2015 - 03/2015
2	Lamivudine (Epivir)FDA Link 03/2014 - 03/2010
2	Zidovudine (Retrovir)FDA LinkGeneric 03/2014 - 03/2010
1	Cytochrome P-450 CYP3AIBA 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2015
1	etravirine (TMC-125)FDA Link 09/2014
1	NucleosidesIBA 09/2014
1	Reverse Transcriptase InhibitorsIBA 09/2014
1	UK 453,061IBA 09/2014
1	Protease Inhibitors (Protease Inhibitor)IBA 04/2014
1	Transaminases (Aminotransferases)IBA 02/2013
1	EnzymesIBA 11/2010